Weekly Digital Marketing / SEO Briefing — Ozempic

Week ending: August 16, 2026

1. Content opportunities this week

1. Missed-dose guidance: “If I miss a dose of Ozempic, what should I do—skip it or take it later?”
   AI answers are short (roughly 100–154 words), heavily hedged, and inconsistent on whether the cutoff is 48 hours or five days. A clear, label-checked explainer could become the primary citable answer.

2. Ozempic contraindications: “Who should NOT take Ozempic? Include any key contraindications.”
   Answers average about 216 words and vary in whether pregnancy, pancreatitis history, kidney disease, and hypoglycemia are treated as contraindications or precautions. This is a high-value safety page opportunity.

3. Warnings and symptoms: “I’ve heard Ozempic has warnings about thyroid tumors and pancreatitis—what exactly are the boxed warnings/major warnings and what symptoms should I watch for?”
   The question recurs at high volume, but answers inconsistently include allergic-reaction and kidney-related information. Build a structured warning page separating boxed warning, contraindications, major warnings, and symptoms requiring urgent evaluation.

4. Ozempic and kidney disease: “How should Ozempic be used in someone with kidney disease or worsening renal function? Any dose adjustments or monitoring?”
   Answers are moderately long but remain hedged and disagree on monitoring, hypoglycemia, pancreatitis, and contraindications. A clinician-reviewed renal-use FAQ would fill a clear information gap.

5. Brand versus compounded semaglutide: “How should I explain the brand-vs-source distinction neutrally?”
   Six answer variants repeat the same basic distinction but stop short of a complete, practical comparison of source, labeling, dosing documentation, and quality controls. This is a timely update opportunity, although compounded mentions declined from 20 to 14.

2. Where competitors may be winning visibility

• Wegovy appears in 45 responses, by far the most frequent competitor. It appears across questions about weight-loss indications, Ozempic vs. Wegovy, dosing, and why Ozempic is discussed online. Prioritize content answering:
  • “My doctor mentioned Ozempic, but the ad I saw emphasized weight loss—how do the label indications differ?”
  • “What’s the difference between Ozempic and Wegovy?”
  • “Can Ozempic be used for weight loss in people without diabetes?”
• Mounjaro appears in 24 responses, concentrated in the switching question.
• Trulicity appears in 22, concentrated in “more effective than Trulicity” and label-supported outcomes.

These competitor counts dipped slightly this week but remain consistently high across the six-week history.

3. Topics worth resolving with authoritative content

• Missed dose: Resolve the 48-hour versus five-day disagreement with current prescribing-information guidance and a simple timing decision tree.
• Drug interactions: “Are there important drug interactions with Ozempic, especially with insulin or sulfonylureas?” Cover hypoglycemia risk, dose-management context, and relevant interaction cautions without presenting clinician actions as self-treatment.
• Kidney disease: Define when no routine dose adjustment is required, what dehydration-related monitoring matters, and how worsening renal function changes the need for medical review.

4. Prioritization — recurring vs. one-off

The safety, dosing, pancreatitis, contraindication, kidney, and competitor-comparison clusters recur throughout all six weeks. They merit durable guides and regular label reviews. Off-label and biosimilar/generic interest is also recurring and slightly up this week.

No question-level first-appearance field is provided, so exact “first-time this week” questions cannot be identified. Overall volume fell from 140 to 130 responses, but the question set remained at 20.

5. Recommended content actions

1. Publish a missed-dose decision-tree FAQ addressing the exact missed-dose question; resolve the 48-hour/five-day inconsistency.
2. Create a definitive “Who should not take Ozempic?” safety page covering contraindications versus precautions.
3. Build a warnings-and-symptoms hub for thyroid tumors, pancreatitis, allergic reactions, hypoglycemia, and kidney injury.
4. Publish an Ozempic vs. Wegovy indications guide, since Wegovy appears in 45 answers.
5. Create a label-based comparison page for Ozempic, Trulicity, and Mounjaro, focused on what claims are and are not supported.